These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 27320035)

  • 21. Fertility outcomes in women after controlled ovarian stimulation with gonadotropin releasing hormone agonist long protocol: fresh versus frozen embryo transfer.
    Ding X; Yang J; Li L; Yang N; Lan L; Huang G; Ye H
    BMC Pregnancy Childbirth; 2021 Mar; 21(1):207. PubMed ID: 33711956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotrophin-releasing hormone antagonists for assisted conception.
    Al-Inany H; Aboulghar M
    Cochrane Database Syst Rev; 2001; (4):CD001750. PubMed ID: 11687120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian stimulation increases the risk of ectopic pregnancy for fresh embryo transfers: an analysis of 68,851 clinical pregnancies from the Japanese Assisted Reproductive Technology registry.
    Jwa SC; Seto S; Takamura M; Kuwahara A; Kajihara T; Ishihara O
    Fertil Steril; 2020 Dec; 114(6):1198-1206. PubMed ID: 33081977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes.
    Styer AK; Gaskins AJ; Brady PC; Sluss PM; Chavarro JE; Hauser RB; Toth TL
    Fertil Steril; 2015 Nov; 104(5):1153-61.e1-7. PubMed ID: 26315051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial.
    Boostanfar R; Gates D; Guan Y; Gordon K; McCrary Sisk C; Stegmann BJ
    Fertil Steril; 2016 Aug; 106(2):300-305.e5. PubMed ID: 27090863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols.
    Toftager M; Sylvest R; Schmidt L; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Pinborg A
    Fertil Steril; 2018 Jan; 109(1):154-164. PubMed ID: 29175067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are gonadotropin-releasing hormone agonists losing popularity? Current trends at a large fertility center.
    Reh A; Krey L; Noyes N
    Fertil Steril; 2010 Jan; 93(1):101-8. PubMed ID: 18973891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology.
    Yeh JS; Steward RG; Dude AM; Shah AA; Goldfarb JM; Muasher SJ
    Fertil Steril; 2014 Aug; 102(2):399-404. PubMed ID: 24842672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
    Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
    Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled ovarian hyperstimulation for in vitro fertilization alters endometrial receptivity in humans: protocol effects.
    Haouzi D; Assou S; Dechanet C; Anahory T; Dechaud H; De Vos J; Hamamah S
    Biol Reprod; 2010 Apr; 82(4):679-86. PubMed ID: 20042535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist IVF cycles.
    Sahin S; Ozay A; Ergin E; Turkgeldi L; Kürüm E; Ozornek H
    Arch Gynecol Obstet; 2015 Jan; 291(1):185-91. PubMed ID: 25078054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.
    Martínez F; Rodríguez DB; Buxaderas R; Tur R; Mancini F; Coroleu B
    Fertil Steril; 2011 Jun; 95(7):2432.e17-9. PubMed ID: 21513932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.